---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-016381"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2025-01-30T23:59:59+00:00"
generated_at: "2026-05-27T05:17:37.522460+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Lantheus appoints Dr. Phuong Khanh Morrow to board, effective Feb 1, 2025

## Summary
- Dr. Phuong Khanh Morrow appointed independent director effective Feb 1, 2025; board expands to 11.
- Morrow is Head of Oncology TAU at Takeda, former CMO at CRISPR Therapeutics, and VP at Amgen.
- Will receive $60k annual cash retainer, $7.5k STC fee, initial $100k equity grant (50% RSU, 50% options), and $400k annual equity.
- Appointed to Science and Technology Committee; board now has 11 directors, 9 independent.

## SEC filing metadata
- accession: 0001193125-25-016381
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2025-01-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312525016381/0001193125-25-016381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312525016381/d838877d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-016381
- JSON: https://secwatch.observer/filing/0001193125-25-016381.json
- Plain text: https://secwatch.observer/filing/0001193125-25-016381.txt

## Key facts
- Executive change
  Phuong Khanh Morrow was appointed as Director at Lantheus Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 29, 2025, the board of directors of Lantheus Holdings, Inc. (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Phuong Khanh (P.K.) Morrow, M.D., an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology, to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1521036/000119312525016381/0001193125-25-016381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.